Home › NDC Lookup › RxCUI directory › RxCUI 901401

Doxycycline anhydrous 40 MG Delayed Release Oral Capsule [Oracea] — RxCUI 901401

RxNorm drug concept · Semantic branded drug
RxCUI 901401 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI901401
Official nameDoxycycline anhydrous 40 MG Delayed Release Oral Capsule [Oracea]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asOracea 40 MG Delayed Release Oral Capsule
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)51 prescriptions · 1 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Doxycycline Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • The IV form is used when you're not able to swallow or absorb oral medication — for example, if you're too sick, vomiting, or need a faster, more reliable delivery of the antibioti...
  • Why am I getting doxycycline through an IV instead of just taking a pill?
  • It depends on what infection you're being treated for. For most infections, treatment continues for at least 24 to 48 hours after your fever and symptoms have cleared. For somethin...
  • How long will I need to be on this antibiotic?
📖 Read our full Doxycycline Injection guide →

🕸️ Concept Web — How Doxycycline anhydrous 40 MG Delayed Release Oral... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Doxycycline anhydrous 40 MG Delayed Release Oral Capsule [Oracea] RxCUI 901401

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Doxycycline 3640
    • Doxycycline anhydrous 1545992
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Oracea 643822
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Doxycycline Delayed Release Oral Capsule 378209
    • Doxycycline anhydrous Delayed Release Oral Capsule 2647975
    • Doxycycline Oral Product 1160778
    • Doxycycline Pill 1160779
    • Doxycycline anhydrous Oral Product 2663160
    • Doxycycline anhydrous Pill 2661725
    • Doxycycline Delayed Release Oral Capsule [Oracea] 901400
    • Doxycycline anhydrous Delayed Release Oral Capsule [Oracea] 2656574
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Doxycycline anhydrous 40 MG Delayed Release Oral Capsule SCD · 901399
  • Doxycycline anhydrous 40 MG SCDC · 1653353
  • Doxycycline Delayed Release Oral Capsule SCDF · 378209
  • Doxycycline anhydrous Delayed Release Oral Capsule SCDFP · 2647975
  • Doxycycline Oral Product SCDG · 1160778
  • Doxycycline Pill SCDG · 1160779
  • Doxycycline anhydrous Oral Product SCDGP · 2663160
  • Doxycycline anhydrous Pill SCDGP · 2661725

Brand-Name Concepts

  • Doxycycline anhydrous 40 MG [Oracea] SBDC · 1653355
  • Doxycycline Delayed Release Oral Capsule [Oracea] SBDF · 901400
  • Doxycycline anhydrous Delayed Release Oral Capsule [Oracea] SBDFP · 2656574
  • Oracea Oral Product SBDG · 1182896
  • Oracea Pill SBDG · 1182897
  • Oracea BN · 643822

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 901401 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00299-3822-30 30 CAPSULE in 1 BOTTLE (0299-3822-30) ORACEA Galderma Laboratories, L.P. 2010-05-14
Observed labelers: Galderma Laboratories, L.P. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$29.0899
Range $29.0899–$29.0899 · middle 50% $29.0899–$29.0899 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.